Innovation Pharmaceuticals Inc. (IPIX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerInnovation Pharmaceuticals Inc. (IPIX) trades at $0.0001. Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for various medical conditions. Its lead candidate, Brilacidin, targets multiple diseases, including oral mucositis and COVID-19. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for IPIX: IPIX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Innovation Pharmaceuticals Inc. (IPIX) Healthcare & Pipeline Overview
Innovation Pharmaceuticals Inc. specializes in developing innovative small molecule therapies, with a focus on addressing unmet medical needs in inflammatory diseases, cancer, and infectious conditions, positioning itself as a key player in the biotechnology sector.
What Is the Investment Thesis for IPIX?
Innovation Pharmaceuticals Inc. presents a unique investment thesis driven by its promising pipeline of drug candidates, particularly Brilacidin, which is currently in various stages of clinical trials. The company’s focus on multiple therapeutic areas, including oncology and infectious diseases, positions it to capitalize on significant market opportunities. As the clinical trials progress, successful outcomes could lead to potential partnerships or acquisitions, enhancing the company’s valuation. However, investors should be mindful of the inherent risks associated with clinical-stage companies, including regulatory hurdles and the uncertainty of trial outcomes.
Based on FMP financials and quantitative analysis
IPIX Key Highlights
Market Cap: $0.00B, indicating a nascent stage in market presence.
- Beta: -0.49, suggesting lower volatility compared to the broader market.
- No dividend yield, reflecting a focus on reinvestment in R&D.
- Small team of 4 employees, emphasizing a lean operational structure.
- Strong pipeline with Brilacidin as a lead candidate targeting multiple indications.
Who Are IPIX's Competitors?
IPIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AMRN Amarin Corporation plc | $12.35 | -2.91% | $255M | — |
| NDAQ Nasdaq, Inc. | $90.33 | -1.46% | $50.5B | 77 5-pillar |
| NVO Novo Nordisk A/S | $37.32 | -0.21% | $166B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | — |
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | — |
| ARGX argenx SE | $919.21 | -1.79% | $57.2B | — |
| ALNY Alnylam Pharmaceuticals, Inc. | $219.72 | -4.96% | $29.4B | — |
| RPRX Royalty Pharma plc | $57.16 | -0.82% | $25.3B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IPIX's Key Strengths?
Innovative pipeline with lead candidate Brilacidin targeting multiple diseases.
- Strong focus on small molecule therapies addressing significant medical needs.
- Established partnerships that enhance research and development capabilities.
What Are IPIX's Weaknesses?
Limited operational scale with only 4 employees.
- Dependence on successful clinical trial outcomes for future growth.
- No current revenue stream, relying on external funding.
What Are the Key Risks for IPIX?
Financial-distress signal — its Altman Z-Score of -28.45 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-93.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory approval delays could hinder the commercialization of drug candidates.
- Market competition from larger biotechnology firms may impact growth.
- Clinical trial failures could lead to significant financial setbacks.
What Threats Does IPIX Face?
- Regulatory hurdles and challenges in obtaining FDA approvals.
- High competition in the biotechnology sector from larger firms.
- Market volatility impacting funding and investment opportunities.
What Are IPIX's Competitive Advantages?
- Innovative drug candidates with potential for multiple indications.
- Strategic partnerships that enhance research capabilities and market access.
- Focus on rare and underserved medical conditions with high unmet needs.
- Small operational footprint allowing for agile decision-making and resource allocation.
What Does IPIX Do?
Innovation Pharmaceuticals Inc., founded in 2005 and headquartered in Wakefield, Massachusetts, operates as a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Initially known as Cellceutix Corporation, the company rebranded to its current name in June 2017 to better reflect its focus on innovation in pharmaceuticals. The company's pipeline includes a diverse range of therapeutic areas, specifically targeting inflammatory diseases, cancer, dermatology, and infectious conditions. Its lead drug candidate, Brilacidin, is currently undergoing clinical trials for several indications, including oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infections, and COVID-19. Additionally, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound that is being investigated for its potential in treating ovarian cancer. The company has established strategic partnerships, including a license agreement with Alfasigma S.p.A. and a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc., which enhance its research capabilities and market reach. With a small team of four employees, Innovation Pharmaceuticals is focused on leveraging its innovative drug candidates to address significant medical needs and improve patient outcomes.
What Products and Services Does IPIX Offer?
- Develops small molecule therapies for various medical conditions.
- Focuses on clinical-stage drug development in oncology and infectious diseases.
- Conducts research and clinical trials to validate drug efficacy and safety.
- Collaborates with strategic partners to enhance research capabilities.
- Targets unmet medical needs in inflammatory diseases and cancer.
- Operates with a lean team to maximize resource efficiency.
How Does IPIX Make Money?
- Generates revenue through potential partnerships and licensing agreements.
- Focuses on advancing drug candidates through clinical trials to attract investment.
- Seeks to commercialize successful therapies to address market needs.
- Utilizes strategic collaborations to enhance research and development efforts.
- Aims to secure funding through grants and public offerings as drug candidates progress.
What Industry Does IPIX Operate In?
The biotechnology industry is characterized by rapid innovation and significant growth potential, driven by advancements in drug discovery and increasing demand for novel therapies. Innovation Pharmaceuticals Inc. operates within this dynamic landscape, focusing on small molecule therapies that address unmet medical needs in various therapeutic areas. The competitive landscape includes numerous players, but Innovation Pharmaceuticals differentiates itself through its targeted approach and innovative drug candidates, particularly Brilacidin and Kevetrin.
Who Are IPIX's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from inflammatory diseases and cancer.
- Pharmaceutical partners interested in licensing or collaboration.
- Research institutions conducting clinical trials and studies.
- Investors looking for opportunities in the biopharmaceutical sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Innovation Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wakefield, US. The company is led by CEO Leo Ehrlich. IPIX has traded publicly since 2007.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Innovation Pharmaceuticals Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.45 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Innovation Pharmaceuticals Inc. stands at -93.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.1%, showing how much profit it generates from its asset base. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching.
IPIX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IPIX Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
IPIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IPIX.
Price Targets
Wall Street price target analysis for IPIX.
IPIX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IPIX; grades run from A+ (80-100) to F (below 30).
Leadership: Leo Ehrlich
CEO
Leo Ehrlich has a background in finance and management, with extensive experience in the biopharmaceutical sector. He has held various leadership roles and has been instrumental in guiding Innovation Pharmaceuticals through its transition from Cellceutix Corporation. His educational background includes a focus on business administration, providing him with the skills necessary to navigate the complexities of the pharmaceutical industry.
Track Record: Under Leo Ehrlich's leadership, Innovation Pharmaceuticals has successfully transitioned its brand and focused on developing innovative therapies. His strategic decisions have led to the advancement of key drug candidates and the establishment of valuable partnerships.
IPIX OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher-tier OTC markets or major exchanges like NYSE or NASDAQ. These companies may have limited public information and lower liquidity, making them riskier investments.
- OTC Tier: OTC Other
- Limited liquidity can hinder the ability to buy or sell shares without impacting the stock price significantly.
- Regulatory scrutiny may increase, leading to potential compliance challenges.
- Market perception of OTC stocks can lead to undervaluation compared to listed peers.
- Review the company's clinical trial results and progress.
- Evaluate the financial health and funding sources.
- Investigate the management team's track record and experience.
- Assess the competitive landscape and market positioning.
- Monitor regulatory developments and potential approval timelines.
- Established partnerships with reputable organizations.
- Active engagement in clinical trials and research.
- Transparency in communications and disclosures.
IPIX Healthcare Stock FAQ
What are the key growth opportunities for IPIX in healthcare?
Innovation Pharmaceuticals Inc. has several growth opportunities, including the expansion of Brilacidin's applications in treating oral mucositis and COVID-19, which could tap into a market projected to reach $1.2 billion by 2027.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Data is based on available information and may be subject to change.